Loading...

Applied Therapeutics

DB:2UV
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2UV
DB
$143M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. The last earnings update was 110 days ago. More info.


Add to Portfolio Compare Print
2UV Share Price and Events
7 Day Returns
-4.8%
DB:2UV
-1.1%
DE Biotechs
-0.4%
DE Market
1 Year Returns
-
DB:2UV
-14.2%
DE Biotechs
-6.2%
DE Market
2UV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Applied Therapeutics (2UV) -4.8% -14.4% - - - -
DE Biotechs -1.1% -5.2% 4.8% -14.2% 76.4% 3%
DE Market -0.4% 0.7% 1.8% -6.2% 13.9% 7.5%
1 Year Return vs Industry and Market
  • No trading data on 2UV.
  • No trading data on 2UV.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Applied Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Applied Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Applied Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Applied Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €7.5.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Applied Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Applied Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2UV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.01
NasdaqGM:APLT Share Price ** NasdaqGM (2019-06-25) in USD $8.41
Europe Biotechs Industry PE Ratio Median Figure of 29 Publicly-Listed Biotechs Companies 21.48x
Germany Market PE Ratio Median Figure of 425 Publicly-Listed Companies 19.49x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Applied Therapeutics.

DB:2UV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:APLT Share Price ÷ EPS (both in USD)

= 8.41 ÷ -3.01

-2.79x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Applied Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Applied Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Applied Therapeutics's expected growth come at a high price?
Raw Data
DB:2UV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.79x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-21.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 23 Publicly-Listed Biotechs Companies 1.02x
Germany Market PEG Ratio Median Figure of 271 Publicly-Listed Companies 1.45x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Applied Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Applied Therapeutics's assets?
Raw Data
DB:2UV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-3.55
NasdaqGM:APLT Share Price * NasdaqGM (2019-06-25) in USD $8.41
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.14x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.8x
DB:2UV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:APLT Share Price ÷ Book Value per Share (both in USD)

= 8.41 ÷ -3.55

-2.37x

* Primary Listing of Applied Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Applied Therapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Examine Applied Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Applied Therapeutics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Applied Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Applied Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Applied Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-21.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Applied Therapeutics expected to grow at an attractive rate?
  • Unable to compare Applied Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Applied Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Applied Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:2UV Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2UV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -21.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 44.9%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 32.3%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2UV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2UV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 72 -57 2
2022-12-31 25 -97 2
2021-12-31 19 -98 1
2020-12-31 4 -55 1
2019-12-31 0 -34 2
DB:2UV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -11 -17
2017-12-31 -3 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Applied Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Applied Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2UV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Applied Therapeutics Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2UV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -1.26 -0.57 -1.95 2.00
2022-12-31 -2.44 -1.27 -3.60 2.00
2021-12-31 -2.61 -1.41 -3.90 3.00
2020-12-31 -2.70 -1.81 -3.25 3.00
2019-12-31 -2.46 -1.90 -2.81 3.00
DB:2UV Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.01
2017-12-31 -0.79

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Applied Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Applied Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Applied Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Applied Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Applied Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Applied Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Applied Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Applied Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Applied Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Applied Therapeutics Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2UV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -16.52 2.05 11.47
2017-12-31 -4.28 0.58 3.70

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Applied Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Applied Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Applied Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Applied Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Applied Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Applied Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Applied Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Applied Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Applied Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Applied Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Applied Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Applied Therapeutics Company Filings, last reported 5 months ago.

DB:2UV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 15.82 0.00 18.75
2017-12-31 2.29 0.00 3.28
  • Applied Therapeutics has no debt.
  • Applied Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Applied Therapeutics has sufficient cash runway for 1.7 years based on current free cash flow.
  • Applied Therapeutics has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 111.2% each year.
X
Financial health checks
We assess Applied Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Applied Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Applied Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Applied Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Applied Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Applied Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Applied Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2UV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2UV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Applied Therapeutics has not reported any payouts.
  • Unable to verify if Applied Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Applied Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Applied Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Applied Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Applied Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Applied Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Applied Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Applied Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Shoshana Shendelman
AGE 39
CEO Bio

Dr. Shoshana Shendelman, PhD is the Founder of Applied Therapeutics Inc. and serves as its Chairman, President, Chief Executive Officer and Secretary. Dr. Shendelman has been Director of Applied Therapeutics Inc. since January 2016. Prior to founding Applied, Dr. Shendelman founded Clearpoint Strategy Group, a boutique strategic advisory firm in NYC, where she serves as a Senior Advisor. Dr. Shendelman has directed products through early and late stage development, from conceptual design to product launch for clients including top 10 pharmaceutical companies, biotech start-ups, and VC firms. She received her doctorate from Columbia University in Cellular, Molecular, and Biophysical Studies (CMBS), where her graduate work focused on neuronal stem cell differentiation and molecular mechanisms of Parkinson’s disease.

CEO Compensation
  • Insufficient data for Shoshana to compare compensation growth.
  • Insufficient data for Shoshana to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Shoshana Shendelman

TITLE
Chairman
AGE
39

Mark Vignola

TITLE
Chief Financial Officer
AGE
41
TENURE
0.2 yrs

Riccardo Perfetti

TITLE
Chief Medical Officer
AGE
58
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Applied Therapeutics board of directors in years:

0.2
Average Tenure
61
Average Age
  • The average tenure for the Applied Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Shoshana Shendelman

TITLE
Chairman
AGE
39

Donald Landry

TITLE
Chairman of Scientific Advisory Board
AGE
63

Teena Lerner

TITLE
Director
AGE
60
TENURE
2.3 yrs

Jay Skyler

TITLE
Director
AGE
71
TENURE
0.2 yrs

Stacy Kanter

TITLE
Director
AGE
59
TENURE
0.1 yrs

Gregg Stone

TITLE
Member of Scientific Advisory Board
AGE
61

Larry Steinman

TITLE
Member of Scientific Advisory Board
AGE
70

Roxana Mehran

TITLE
Member of Scientific Advisory Board

Roy Freeman

TITLE
Member of Scientific Advisory Board

Andrew Wasmuth

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Applied Therapeutics individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
21. May 19 Buy Alexandria Venture Investments, LLC Company 16. May 19 16. May 19 975,000 €8.95 €8,724,300
20. May 19 Buy Joel Marcus Individual 16. May 19 16. May 19 150,000 €8.95 €1,342,200
20. May 19 Buy Shoshana Shendelman Individual 16. May 19 16. May 19 125,000 €8.95 €1,118,500
X
Management checks
We assess Applied Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Applied Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company’s preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

Details
Name: Applied Therapeutics, Inc.
2UV
Exchange: DB
Founded: 2016
$125,895,588
17,052,202
Website: http://www.appliedtherapeutics.com
Address: Applied Therapeutics, Inc.
340 Madison Avenue,
19th Floor,
New York,
New York, 10173,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM APLT Common Stock Nasdaq Global Market US USD 14. May 2019
DB 2UV Common Stock Deutsche Boerse AG DE EUR 14. May 2019
Number of employees
Current staff
Staff numbers
4
Applied Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/26 04:19
End of day share price update: 2019/06/25 00:00
Last estimates confirmation: 2019/06/24
Last earnings filing: 2019/03/08
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.